Glioma Susceptibility 1; Glm1
Description
Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, ependymomas, and subependymomas. Glial cells can show various degrees of differentiation even within the same tumor (summary by Kyritsis et al., 2010).Ependymomas are rare glial tumors of the brain and spinal cord (Yokota et al., 2003).Subependymomas are unusual tumors believed to arise from the bipotential subependymal cell, which normally differentiates into either ependymal cells or astrocytes. They were characterized as a distinct entity by Scheinker (1945). They tend to be slow-growing, noninvasive, and located in the ventricular system, septum pellucidum, cerebral aqueduct, or proximal spinal cord (summary by Ryken et al., 1994).Gliomas are known to occur in association with several other well-defined hereditary tumor syndromes such as mismatch repair cancer syndrome (OMIM ), melanoma-astrocytoma syndrome (OMIM ), neurofibromatosis-1 (NF1 ) and NF2 (OMIM ), and tuberous sclerosis (TSC1 ). Familial clustering of gliomas may occur in the absence of these tumor syndromes, however.
Clinical Features
Top most frequent phenotypes and symptoms related to Glioma Susceptibility 1; Glm1
- Neoplasm
- Hydrocephalus
- Polyhydramnios
- Melanoma
- Growth abnormality
- Neurofibromas
- Brain neoplasm
- Astrocytoma
- Glioma
- Schwannoma
And another 4 symptoms. If you need more information about this disease we can help you.
Incidence and onset information
— Based on the latest data available GLIOMA SUSCEPTIBILITY 1; GLM1 have a estimated prevalence of 10 per 100k worldwide.— No data available about the known clinical features onset.
Researches and researchers
Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.Glioma Susceptibility 1; Glm1 Recommended genes panels
Panel Name, Specifity and genes Tested/covered |
---|
TP53 Comprehensive - Sequence & Deletion/Duplication Analysis.
By Baylor Miraca Genetics Laboratories (United States).
TP53
Specificity
100 %
Genes
34 % |
TP53 Deletion/Duplication Analysis.
By Baylor Miraca Genetics Laboratories (United States).
TP53
Specificity
100 %
Genes
34 % |
TP53 Sequence Analysis.
By Baylor Miraca Genetics Laboratories (United States).
TP53
Specificity
100 %
Genes
34 % |
TP53 Sequence Analysis (Familial Mutation/Variant Analysis).
By Baylor Miraca Genetics Laboratories (United States).
TP53
Specificity
100 %
Genes
34 % |
MitoMet®Plus aCGH Analysis.
By Baylor Miraca Genetics Laboratories (United States).
RGS9, RHO, GRK1, RLBP1, RNASEL, BCS1L, RP1, RP2, RP9, RPE65, RPGR, RPL35A, MRPL3, RPS14, RS1, SAG, SARDH, SCO2, SCP2, SDHB , (...)
View the complete list with 612 more genes
Specificity
1 %
Genes
34 % |
Hereditary Brain, CNS, PNS Cancer Panel.
By Baylor Miraca Genetics Laboratories (United States).
TP53, VHL, SUFU, PALB2, ALK, APC, MEN1, MLH1, MRE11, MSH2, MSH6, NBN, NF2, ATM, PMS2, PHOX2B, PTCH1
Specificity
6 %
Genes
34 % |
Hereditary High Risk Breast Cancer Panel.
By Baylor Miraca Genetics Laboratories (United States).
BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN
Specificity
15 %
Genes
34 % |
Hereditary Brain, CNS, PNS Cancer Panel.
By Baylor Miraca Genetics Laboratories (United States).
TP53, VHL, SUFU, PALB2, ALK, APC, MEN1, MLH1, MRE11, MSH2, MSH6, NBN, NF2, ATM, PMS2, PHOX2B, PTCH1
Specificity
6 %
Genes
34 % |
You can get up to 459 more panels with our dedicated tool
Learn moreSources and references
You can check the following sources for additional information.
OMIM ORPHANET Rare Disease Search EngineIf you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 3; MDDGB3 FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1 DYSTONIA 9; DYT9 MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY RUIJS-AALFS SYNDROME; RJALS MOEBIUS SYNDROME NEUROECTODERMAL-ENDOCRINE SYNDROME